Background:The SARS-CoV-2 virus has caused a pandemic infection called COVID-19. It is a globalthreat to people, communities, and health systems. Researchers are concerned about themental health effects of the pandemic. They want to learn more about how it is affectingpeople s alcohol use and problems, and how it may continue to affect them over time.Objective:To study the impact of the COVID-19 pandemic on alcohol use and consequences inindividuals across the spectrum of alcohol use and those with alcohol use disorder.Eligibility:Participants who have been screened under the NIAAA Screening, Assessment and ManagementProtocol (14-AA-0181)Design:Participants will complete a baseline survey by phone. It will ask about alcohol use,alcohol dependence, and stress. It covers 2 time periods: the 12 months before thepandemic started and the time since it started.Participants will get an ID code and a link to an online survey. They will complete theonline survey within a week of the phone survey.Participants will complete a series of online surveys over 24 months. For the first year,surveys will be completed weekly for the first 4 weeks, then biweekly for the next 8weeks, and then every 1-2 months for the rest of the year. For the second year, surveyswill be completed every 6 months. Surveys will cover the following topics: - Alcohol use and its consequences - Other substance use - Stress - Impact of the COVID-19 pandemic - Pain - Physical health - Sleep - Quality of life.Because the course of the pandemic may change, the frequency of the surveys may change.Participation lasts 2 years.

The Coronavirus disease 2019 (COVID-19) had its outbreak in late 2019 in China and isconsidered a biological disaster. With medical organizations and staff on the frontline,the investigators should conduct assessments, for the different tiers of medical staff,patients, and community residents, on the short- term psychological and mentaldisabilities or danger factors that they might have faced. As such, the investigators candesign and establish a set of evaluative indicators of the risks of biological disasters,and strategies to manage guide and cope, and internal/ external testing strategies. Thesework in guaranteeing quality and performance, and as such, establishing "Digital Platformfor Integrated Research of Coronavirus disease 2019 (COVID-19)".

Primary care physicians face limited availability of therapeutic options for thetreatment of COVID-19 in the outpatient setting. Furthermore, monoclonal antibodies andantiviral therapies that are currently approved for use in the outpatient setting byHealth Canada have excluded pregnant women and older adults from their clinical trials,are contraindicated for many patients, and most are prohibited for use by pregnant women.Identification of a safe, COVID-19 outpatient therapeutic with 20-year safety recordremains urgently needed.

This study collects blood samples, medical information, and medical images from patientswho are being treated for cancer and have a positive test for SARS CoV-2, the newcoronavirus that causes the disease called COVID-19. Collecting blood samples, medicalinformation, and medical images may help researchers determine how COVID-19 affects theoutcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

This expanded access program will provide access to investigational convalescent plasmafor patients in acute care facilities infected with SARS-CoV-2 who have severe orlife-threatening COVID-19, or who are judged by a healthcare provider to be at high riskof progression to severe or life-threatening disease.

In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan,Hubei Province in the People's Republic of China. The disease spreads rapidly and thenumber of sick people is increasing. On January 3, 2020 a new virus of the coronavirusfamily is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhanand subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the WorldHealth Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is apandemic.As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with morethan 16,000 deaths attributed to this virus. (Ref WHOhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019 ).In France, the number of cases rose from 105 cases at the end of February to 19615confirmed cases on March 24. (Source Public Health France). Most of the cases are adults.However, children are not completely spared and serious cases have been described. Thesesevere cases can be respiratory or extra-respiratory (e.g. myocarditis). We also knowthat pediatric and adult cases differ in terms of clinical, biological and imagingfindings, particularly chest CT scans. However, the description of paediatric pictures,especially severe forms and the involvement of children suffering from co-morbidities,remains poorly reported. Finally, the risk factors for serious cases in children remainlargely unknown.This observatory aim to describe the clinical phenotypes of hospitalized pediatricpatients with Covid19 in France, according to age groups. Moreover for a subgroup ofpatients, informations regarding the long covid will be reported.

Our long-term goal is to protect the health care workforce (HCW) caring forSARS-CoV-2-infected patients, their families, communities, and the general population.Our specific objective is to rapidly establish a prospective cohort to characterize thefactors related to viral transmission and disease severity in a large healthcare system.We addressed this hypothesis by recruiting and longitudinally following 546 HCW and acomparison group of 283 non-HCW within a large academic health system, Rutgers Biomedicaland Health Sciences (RBHS). By intensively following participants over a several yearperiod (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs,blood, and saliva) and questionnaire data at multiple time points, we will uniquelycharacterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and ourlarger academic community.

This is a Phase II interventional study testing whether treatment withhydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19

Prospective cohort study of COVID-19 infection among children in Norway.

Predi-COVID is a prospective cohort study composed of people positively tested forCOVID-19 in Luxembourg, followed digitally for monitoring participants' health evolutionand symptoms at home. Participants will be actively followed for 14 days from the time ofconfirmation of diagnosis, whether they are at the hospital or at home in isolation orquarantine. Short evaluations will be also performed at week 3 and week 4 and thenmonthly for a period up to 12 months to assess potential long term consequences ofCOVID-19. A subsample of 200 participants will be contacted to integrate complementaryclinical data and collect samples.The study aims at identifying factors associated with the COVID-19 disease severity.COVID-19 patients with severity criteria will be compared to patients with mild diseasemanaged at home.A deep phenotyping related to the symptoms of the disease as well as biosampling allowingfor laboratory-based and computational analytics will be performed.